Investor Presentaiton

The future of MRD is tissue-free INVESTOR 20 DAY 23 Faster Decreased initial turnaround time to inform adjuvant decision making or to start initial surveillance Easier No need for tissue access for patients in the neoadjuvant, adjuvant settings or who are years out from surgery Powerful Ability to inform clinicians. with precision, detection of heterogeneous cancers, tracking of tumor evolution and more GUARDANT™ 61

View entire presentation